Zoster Virus Vaccine Live (Oka/Merk)
Recommended VaccinesRestrictedNot applicable line
Prevention of herpes zoster (shingles), prevention of postherpetic neuralgia, and reduction of acute and chronic zoster-associated pain in immunocompetent persons aged 60 years and over (ongoing cohort of 60-year-olds and catch-up cohort aged 61–79 years).
3
Submissions
1 resub
2007–08
On the record
$15k–200k
ICER range
3 sourced ICERs · 2007–2008
ICER stated
Cost basis
Decisions on record
- Meeting Nov 2014 Recommended 0.65 mL injection, prefilled syringe Zostavax® bioCSL (Australia) Pty Ltd New listing (Major submission) Immunisation against herpes zoster (shingles) National Immunisation Program (NIP) listing for an ongoing cohort of 70 year old individuals and a catch-up cohort for individuals aged 71-79 years.
- Meeting Mar 2014 Deferred Zostavax® bioCSL (Australia) Pty Ltd Herpes zoster (shingles) Resubmission to reinstate the PBAC recommendation for the listing of zoster virus vaccine live (Zostavax) on the National Immunisation Program (NIP) for the vaccination of an ongoing cohort of 60 year olds and a catch-up cohort of 61 to 7
- Meeting Mar 2008 Recommended Vaccine for shingles
Access path
- 2007Recommended
vs standard medical management (SMM)
- Nov 2007Deferred
ICER rose $45,000 → $200,000 (+344%)
- Mar 2008Recommended · restricted
ICER dropped $200,000 → $45,000 (-78%)
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
ICER range applies to ages 60 and 61–79 years; ages 80+ had ICER $45,000–$75,000 and were not recommended.
The uncertainty around the cost-effectiveness ratio in the younger patient cohorts had been addressed by lowering the price of Zostavax such that in the 60 year old cohort and the 61 to 79 year old cohort, the ICERs per extra QALY gained were between $15,000 to $45,000. PBAC · 2008
ICER uncertain ×2ICER / price too highEconomic model disputedPrice cut / RSA needed
Decision context
PopulationImmunocompetent persons aged 60 years and over, including an ongoing cohort of 60-year-olds and a catch-up cohort for individuals aged 61–79 years.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2008 | Recommended · restricted | standard medical management | $15k–45k | RCT · QoL |
| Nov 2007 | Deferred | standard medical management (SMM) with placebo | $15k–200k | RCT · PHN |
| 2007 | Recommended | standard medical management (SMM) | $15k–45k | RCT · OS | PFS | DFS | ORR | QoL | Surrogate | Cost-minimisation | Other (incidence of herpes zoster, post-herpetic neuralgia, quality of life) |
Similar precedents
Zoster Virus Vaccine Live94%Varicella Zoster Virus Recombinant Vaccine82%Recombinant Varicella Zoster Virus Glycoprotein E Antigen (As01b Adjuvanted) Vaccine81%Influenza Vaccine70%Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine69%Rotavirus Vaccine, Live, Oral Liquid, Pentavalent69%Human Rotavirus Vaccine67%Inactivated Trivalent Influenza Vaccine (Split Virion)66%